| | Identification | Back Directory |  | [Name] 
 10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 4-amino-9-ethyl-1,2,3,9,12,15-hexahydro-9-hydroxy-, (9S)-
 |  | [CAS] 
 2495742-21-5
 |  | [Synonyms] 
 (4-NH2)-Exatecan
 10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 4-amino-9-ethyl-1,2,3,9,12,15-hexahydro-9-hydroxy-, (9S)-
 |  | [Molecular Formula] 
 C23H21N3O4
 |  | [MOL File] 
 2495742-21-5.mol
 |  | [Molecular Weight] 
 403.43
 | 
 | Chemical Properties | Back Directory |  | [Boiling point ] 
 856.1±65.0 °C(Predicted)
 |  | [density ] 
 1.53±0.1 g/cm3(Predicted)
 |  | [storage temp. ] 
 4°C, away from moisture
 |  | [form ] 
 Solid
 |  | [pka] 
 11.23±0.20(Predicted)
 |  | [color ] 
 Light yellow to yellow
 | 
 | Hazard Information | Back Directory |  | [Uses] 
 (4-NH2)-Exatecan, a topoisomerase inhibitor, is a derivative of Exatecan. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs) (US20200306243A1, compound A)[1].
 |  | [Biological Activity] 
 (4-NH2)-Exatecan, a topoisomerase inhibitor derivative extracted from patent US20200306243A1, compound A. (4-NH2)-Exatecan can be used in the synthesis of antibody-drug conjugates (ADCs)[1].
 |  | [IC 50] 
 Camptothecins
 |  | [References] 
 [1]. Howard PW, et, al. Compounds and conjugates thereof. US20200306243A1.
 | 
 | Spectrum Detail | Back Directory |  | [Spectrum Detail] 
 10H,13H-Benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10,13-dione, 4-amino-9-ethyl-1,2,3,9,12,15-hexahydro-9-hydroxy-, (9S)-(2495742-21-5)1HNMR
 
 | 
 |  |